Published in Biol Psychiatry on February 15, 2005
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry (2010) 4.85
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov (2008) 4.46
Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol (2009) 2.33
Ketamine for depression: where do we go from here? Biol Psychiatry (2012) 2.21
Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biol Psychiatry (2010) 2.08
The neurobiology of the switch process in bipolar disorder: a review. J Clin Psychiatry (2010) 1.94
Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment. Pharmacol Ther (2011) 1.71
Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry (2006) 1.51
Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx (2006) 1.43
Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry (2010) 1.42
Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs (2012) 1.38
Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole. Neuropsychopharmacology (2009) 1.36
Target identification for CNS diseases by transcriptional profiling. Neuropsychopharmacology (2008) 1.32
Bipolar disorder and mechanisms of action of mood stabilizers. Brain Res Rev (2009) 1.31
Review of pharmacological treatment in mood disorders and future directions for drug development. Neuropsychopharmacology (2011) 1.28
Identification of pathways for bipolar disorder: a meta-analysis. JAMA Psychiatry (2014) 1.26
Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annu Rev Pharmacol Toxicol (2014) 1.21
Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets. NeuroRx (2006) 1.19
Tryptophan kynurenine metabolism as a common mediator of genetic and environmental impacts in major depressive disorder: the serotonin hypothesis revisited 40 years later. Isr J Psychiatry Relat Sci (2010) 1.18
The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist (2009) 1.13
Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders. Curr Pharm Des (2009) 1.08
Targeting glial physiology and glutamate cycling in the treatment of depression. Biochem Pharmacol (2009) 1.07
Brain imaging in pediatric obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry (2008) 1.06
Advances in the treatment of depression. NeuroRx (2006) 1.03
Novel glutamatergic drugs for the treatment of mood disorders. Neuropsychiatr Dis Treat (2013) 1.02
A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders. Eur Arch Psychiatry Clin Neurosci (2008) 1.01
Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice. Psychopharmacology (Berl) (2011) 1.00
Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder. Biol Psychiatry (2007) 1.00
Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression. Bipolar Disord (2012) 0.95
Antidepressant chronotherapeutics for bipolar depression. Dialogues Clin Neurosci (2012) 0.95
New therapeutic targets for mood disorders. ScientificWorldJournal (2010) 0.94
Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: developing treatments using an integrated translational approach. World J Biol Psychiatry (2013) 0.93
Bipolar disorder: involvement of signaling cascades and AMPA receptor trafficking at synapses. Neuron Glia Biol (2004) 0.92
Relationship between genetic variation in the glutaminase gene GLS1 and brain glutamine/glutamate ratio measured in vivo. Biol Psychiatry (2011) 0.91
A complex interaction between glycine/NMDA receptors and serotonergic/noradrenergic antidepressants in the forced swim test in mice. J Neural Transm (Vienna) (2011) 0.91
Advances in the treatment of anxiety: targeting glutamate. NeuroRx (2006) 0.90
Bipolar disorder: candidate drug targets. Mt Sinai J Med (2008) 0.90
The role of BDNF as a mediator of neuroplasticity in bipolar disorder. Psychiatry Investig (2010) 0.89
Mood-stabilizers target the brain arachidonic acid cascade. Curr Mol Pharmacol (2009) 0.89
Riluzole and D-amphetamine interactions in humans. Prog Neuropsychopharmacol Biol Psychiatry (2007) 0.89
Riluzole in psychiatry: a systematic review of the literature. Expert Opin Drug Metab Toxicol (2008) 0.89
A neurobiological hypothesis of treatment-resistant depression - mechanisms for selective serotonin reuptake inhibitor non-efficacy. Front Behav Neurosci (2014) 0.89
Branched-chain amino acids alter neurobehavioral function in rats. Am J Physiol Endocrinol Metab (2012) 0.88
The promise of ketamine for treatment-resistant depression: current evidence and future directions. Ann N Y Acad Sci (2015) 0.88
A pilot study of hippocampal volume and N-acetylaspartate (NAA) as response biomarkers in riluzole-treated patients with GAD. Eur Neuropsychopharmacol (2012) 0.87
Emerging targets for antidepressant therapies. Curr Opin Chem Biol (2009) 0.82
Review of the use of the glutamate antagonist riluzole in psychiatric disorders and a description of recent use in childhood obsessive-compulsive disorder. J Child Adolesc Psychopharmacol (2010) 0.82
New targets for rapid antidepressant action. Prog Neurobiol (2015) 0.81
Future prospects in depression research. Dialogues Clin Neurosci (2006) 0.81
Riluzole likely lacks antidepressant efficacy in ketamine non-responders. J Psychiatr Res (2014) 0.80
Novel targets for antidepressant therapies. Curr Psychiatry Rep (2008) 0.80
Current and emerging therapies for the management of bipolar disorders. J Cent Nerv Syst Dis (2011) 0.79
Translational neuroimaging research in pediatric obsessive-compulsive disorder. Dialogues Clin Neurosci (2010) 0.79
A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia. Psychopharmacology (Berl) (2013) 0.79
Inflammation Models of Depression in Rodents: Relevance to Psychotropic Drug Discovery. Int J Neuropsychopharmacol (2016) 0.78
Lamotrigine blocks NMDA receptor-initiated arachidonic acid signalling in rat brain: implications for its efficacy in bipolar disorder. Int J Neuropsychopharmacol (2011) 0.78
Investigating the mechanism(s) underlying switching between states in bipolar disorder. Eur J Pharmacol (2015) 0.77
Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments. Depress Anxiety (2011) 0.77
Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial. J Clin Psychiatry (2015) 0.77
Proteomic enrichment analysis of psychotic and affective disorders reveals common signatures in presynaptic glutamatergic signaling and energy metabolism. Int J Neuropsychopharmacol (2014) 0.76
Emergent treatments based on the pathophysiology of bipolar disorder: A selective review. Asian J Psychiatr (2015) 0.76
Early intervention in bipolar disorder, part II: therapeutics. Early Interv Psychiatry (2008) 0.76
Promising avenues of therapeutics for bipolar illness. Dialogues Clin Neurosci (2008) 0.76
A Double-Blind, Placebo-Controlled, Pilot Study of Riluzole Monotherapy for Acute Bipolar Depression. J Clin Psychopharmacol (2017) 0.75
Management of obsessive-compulsive disorder comorbid with bipolar disorder. Indian J Psychiatry (2017) 0.75
Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression. Drugs (2017) 0.75
Advances in the Management of Treatment-Resistant Depression. Focus (Am Psychiatr Publ) (2010) 0.75
A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder. Neuropsychopharmacology (2017) 0.75
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry (2006) 11.84
Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry (2007) 6.59
Defining clinical phenotypes of juvenile mania. Am J Psychiatry (2003) 5.49
Discovering endophenotypes for major depression. Neuropsychopharmacology (2004) 4.90
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry (2010) 4.85
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry (2013) 4.84
Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry (2005) 4.81
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov (2008) 4.46
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry (2010) 4.00
Psychobiology and molecular genetics of resilience. Nat Rev Neurosci (2009) 3.71
Abnormal attention modulation of fear circuit function in pediatric generalized anxiety disorder. Arch Gen Psychiatry (2007) 3.10
The psychobiology of depression and resilience to stress: implications for prevention and treatment. Annu Rev Clin Psychol (2005) 3.09
Childhood trauma associated with smaller hippocampal volume in women with major depression. Am J Psychiatry (2002) 3.05
Publication bias and the efficacy of antidepressants. Am J Psychiatry (2009) 3.05
Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry (2009) 3.04
Adolescent immaturity in attention-related brain engagement to emotional facial expressions. Neuroimage (2003) 2.98
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry (2010) 2.98
Ventrolateral prefrontal cortex activation and attentional bias in response to angry faces in adolescents with generalized anxiety disorder. Am J Psychiatry (2006) 2.90
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry (2012) 2.74
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry (2012) 2.69
Reduced volume of orbitofrontal cortex in major depression. Biol Psychiatry (2002) 2.53
MRI and PET study of deficits in hippocampal structure and function in women with childhood sexual abuse and posttraumatic stress disorder. Am J Psychiatry (2003) 2.51
A functional magnetic resonance imaging study of bipolar disorder: state- and trait-related dysfunction in ventral prefrontal cortices. Arch Gen Psychiatry (2003) 2.36
Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol (2009) 2.33
Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry (2006) 2.29
The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci (2003) 2.28
Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch Gen Psychiatry (2007) 2.25
VNS therapy in treatment-resistant depression: clinical evidence and putative neurobiological mechanisms. Neuropsychopharmacology (2006) 2.24
Ketamine for depression: where do we go from here? Biol Psychiatry (2012) 2.21
Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology (2012) 2.17
Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J Neurosci (2004) 2.17
Long-term treatment with paroxetine increases verbal declarative memory and hippocampal volume in posttraumatic stress disorder. Biol Psychiatry (2003) 2.16
Amygdala and hippocampal volumes in adolescents and adults with bipolar disorder. Arch Gen Psychiatry (2003) 2.15
Neurobiology of resilience. Nat Neurosci (2012) 2.13
Toward constructing an endophenotype strategy for bipolar disorders. Biol Psychiatry (2006) 2.09
Differential effects of 5-HTTLPR genotypes on the behavioral and neural responses to tryptophan depletion in patients with major depression and controls. Arch Gen Psychiatry (2006) 2.09
Attention bias to threat in maltreated children: implications for vulnerability to stress-related psychopathology. Am J Psychiatry (2005) 2.08
Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry (2008) 2.05
Life stress, genes, and depression: multiple pathways lead to increased risk and new opportunities for intervention. Sci STKE (2004) 2.04
Positron emission tomographic imaging of neural correlates of a fear acquisition and extinction paradigm in women with childhood sexual-abuse-related post-traumatic stress disorder. Psychol Med (2005) 1.99
Response to emotional expressions in generalized social phobia and generalized anxiety disorder: evidence for separate disorders. Am J Psychiatry (2008) 1.99
Trauma exposure, posttraumatic stress disorder and depression in an African-American primary care population. J Natl Med Assoc (2006) 1.95
The neurobiology of the switch process in bipolar disorder: a review. J Clin Psychiatry (2010) 1.94
Early physical and sexual abuse associated with an adverse course of bipolar illness. Biol Psychiatry (2002) 1.93
Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls. Arch Gen Psychiatry (2004) 1.92
Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology (2005) 1.90
Trauma, resilience, and recovery in a high-risk African-American population. Am J Psychiatry (2008) 1.89
Neural correlates of the classic color and emotional stroop in women with abuse-related posttraumatic stress disorder. Biol Psychiatry (2004) 1.85
A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry (2006) 1.83
AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol (2004) 1.79
Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology (2008) 1.79
A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. Biol Psychiatry (2012) 1.76
Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord (2007) 1.74
Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry (2003) 1.72
Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry (2002) 1.71
An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry (2004) 1.71
Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry (2003) 1.71
Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry (2008) 1.71
Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment. Biol Psychiatry (2004) 1.70
Frontostriatal abnormalities in adolescents with bipolar disorder: preliminary observations from functional MRI. Am J Psychiatry (2003) 1.70
Increased amygdala activity during successful memory encoding in adolescent major depressive disorder: An FMRI study. Biol Psychiatry (2006) 1.68
Rapid and non-rapid cycling bipolar disorder: a meta-analysis of clinical studies. J Clin Psychiatry (2003) 1.68
Regional brain metabolic correlates of alpha-methylparatyrosine-induced depressive symptoms: implications for the neural circuitry of depression. JAMA (2003) 1.67
Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry (2006) 1.65
An overview of posttraumatic stress disorder in African Americans. J Clin Psychol (2006) 1.65
The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology (2006) 1.64
Developing an agenda for translational studies of resilience and vulnerability following trauma exposure. Ann N Y Acad Sci (2006) 1.62
Enduring mental health morbidity and social function impairment in world trade center rescue, recovery, and cleanup workers: the psychological dimension of an environmental health disaster. Environ Health Perspect (2008) 1.62
The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord (2009) 1.62
Deficits in social cognition and response flexibility in pediatric bipolar disorder. Am J Psychiatry (2005) 1.62
Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci (2004) 1.61
Neural correlates of declarative memory for emotionally valenced words in women with posttraumatic stress disorder related to early childhood sexual abuse. Biol Psychiatry (2003) 1.61
Frontotemporal alterations in pediatric bipolar disorder: results of a voxel-based morphometry study. Arch Gen Psychiatry (2005) 1.57
Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry (2008) 1.57
Mood disorders and medical illness: a major public health problem. Biol Psychiatry (2003) 1.56
An integrated approach to evaluate faculty members' research performance. Acad Med (2009) 1.56
A case of sustained remission following an acute course of ketamine in treatment-resistant depression. J Clin Psychiatry (2011) 1.55
Effects of tryptophan depletion on serum levels of brain-derived neurotrophic factor in unmedicated patients with remitted depression and healthy subjects. Am J Psychiatry (2005) 1.55